Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction
- PMID: 39870943
- DOI: 10.1038/s41575-024-01033-9
Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction
Abstract
In patients with disorders of gut-brain interaction (DGBI), overlapping non-gastrointestinal conditions such as fibromyalgia, headaches, gynaecological and urological conditions, sleep disturbances and fatigue are common, as is overlap among DGBI in different regions of the gastrointestinal tract. These overlaps strongly influence patient management and outcome. Shared pathophysiology could explain this scenario, but details are not fully understood. This overlap has been shown to be of great relevance for DGBI. In addition, symptoms considered to be caused by a DGBI could have a detectable organic cause, and in patients with a diagnosed organic gastrointestinal disease, symptoms not clearly explained by the pathology defining this organic disease are common. Thus, the aims of this Rome Foundation Working Team Report were to review the literature on overlapping conditions among patients with paediatric and adult DGBI and, based on the available epidemiological and clinical evidence, make recommendations for the current diagnostic and therapeutic approach, and for future research. Specifically, we focused on other DGBI in the same or different gastrointestinal anatomical region(s), DGBI overlap with organic bowel diseases in remission, and DGBI overlap with non-gastrointestinal, non-structural conditions.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: G.B., L.C., S.N. and M. Simrén are on the Rome Foundation Board of Directors. G.B. declares consultancies, business interests or sources of honoraria payments from Aboca, AB Biotics, Agave, Alfa Sigma, AGPharma, Bayer, Biocodex, Boehringer, Bromatech, Cadigroup, Danone, Diadema, Falk Pharma, GE Healthcare, Giuliani, Mayoly, Malesci, Sanofi, Sofar and Yakult. L.C. is a consultant for AbbVie, Ardelyx, Atmo, Bausch Health, Food Marble, Ironwood Pharmaceuticals, Trellus Health and Vibrant; and receives grant support from AnX Robotica and Ironwood Pharmaceuticals. L.C. also has stock options in Food Marble, ModifyHealth and Trellus Health. S.N. is a consultant for Abbvie. M. Saps is a consultant for AbbVie and Ironwood, and has received study funding from QOL Medical. G.S. is a speaker and consultant for Sanofi/Regeneron, Salix, Phathom, Ardelyx, Ironwood, AbbVie and GI Health Foundation, and is a Council member of the American Neurogastroenterology and Motility Society. M. Simrén. is a consultant for Danone Nutricia Research, Biocodex, Tillotts, Takeda, Kyowa Kirin, Abbvie, BioGaia, Renapharma and Cinclus Pharma; and has received speaker fees from Tillotts, Kyowa Kirin, Takeda, Biocodex, Sanofi, Abbvie, Janssen Immunology, Pfizer, BioGaia, Renapharma, Mayoly and Bromatech. M. Simrén has also received unrestricted research grants from Genetic Analysis AS and BioGaia. The other authors declare no competing interests.
Similar articles
-
A pathophysiologic framework for the overlap of disorders of gut-brain interaction and the role of the gut microbiome.Gut Microbes. 2024 Jan-Dec;16(1):2413367. doi: 10.1080/19490976.2024.2413367. Epub 2024 Oct 31. Gut Microbes. 2024. PMID: 39482844 Free PMC article. Review.
-
Oral Health Is Associated with Disorders of Gut-Brain Interaction in Adult Women.Dig Dis Sci. 2025 Feb;70(2):638-643. doi: 10.1007/s10620-024-08826-7. Epub 2025 Jan 8. Dig Dis Sci. 2025. PMID: 39779585 Free PMC article.
-
Symptom profiles compatible with disorders of gut-brain interaction (DGBI) in organic gastrointestinal diseases: A global population-based study.United European Gastroenterol J. 2024 Sep;12(7):834-847. doi: 10.1002/ueg2.12617. Epub 2024 Jul 8. United European Gastroenterol J. 2024. PMID: 38975964 Free PMC article.
-
Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life.Clin Gastroenterol Hepatol. 2022 May;20(5):e945-e956. doi: 10.1016/j.cgh.2021.05.042. Epub 2021 May 27. Clin Gastroenterol Hepatol. 2022. PMID: 34052391
-
Decoding the Gut-Brain Axis: A Journey toward Targeted Interventions for Disorders-of-Gut-Brain Interaction.Dig Dis. 2025;43(3):257-265. doi: 10.1159/000543845. Epub 2025 Feb 12. Dig Dis. 2025. PMID: 39938496 Review.
Cited by
-
Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.Int J Eat Disord. 2025 Jul;58(7):1345-1351. doi: 10.1002/eat.24449. Epub 2025 Apr 23. Int J Eat Disord. 2025. PMID: 40265508 Free PMC article.
-
Common misconceptions and controversies in the management of irritable bowel syndrome.Nat Rev Gastroenterol Hepatol. 2025 Jul;22(7):517-526. doi: 10.1038/s41575-025-01065-9. Epub 2025 Apr 25. Nat Rev Gastroenterol Hepatol. 2025. PMID: 40281279 Review.
-
Post-COVID-19 Disorders of Gut-Brain Interaction: A New Challenge for Gastroenterologists.United European Gastroenterol J. 2025 Jun;13(5):672-673. doi: 10.1002/ueg2.70008. Epub 2025 Mar 5. United European Gastroenterol J. 2025. PMID: 40045537 Free PMC article. No abstract available.
-
Overlap of 'disorders of gut-brain interaction': A type of diseases that require special attention.Indian J Gastroenterol. 2025 Jul 2. doi: 10.1007/s12664-025-01840-1. Online ahead of print. Indian J Gastroenterol. 2025. PMID: 40601135 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources